With Biotech’s becoming more prominent in today’s market, it is no surprise to investors that stocks in the industry are moving their way back to the top of the stock watch lists in 2015. May has been a good month for biotech investors thus far with many of these biotech stocks seeing rallies of 100% or more within the matter of weeks or even days. While most conservative investors are more attracted to safer, big Pharma companies like Gilead Sciences, Inc. (NASDAQ:GILD) and Amgen, Inc. (NASDAQ:AMGN), retail investors have found small and micro cap biotech stocks to be quite good to to trade on speculative momentum and corporate updates. These are just a few in the buzz cloud of most talked about biotech stocks or trending biotech stocks.
OXIS International Inc. (OTCMKTS:OXIS)- A biotechnology company focused on biotech cancer therapy development and commercialization has set high standards for 2015 after running to highs of $0.07 earlier in the year. With talks from the CEO about up-listing OXIS to the NASDAQ by the end of 2015, the company has made major strides in May. Although the stock is down 4.6% over the last 30 days, those who have taking a “big picture approach have found that the Company has begun to solidify its place within the biotech arena following several announcements firming up the Company’s scientific board. On May 6th OXIS added Cassian Yee, M.D to its scientific advisory board and on May 12th OXIS brought in The Emmes Group to help with its strategic business and therapeutic development initiatives. Over the last 10 days, the stock has seen prices as high as $0.0347 and as low as $0.0287.
Plasmatech Biopharmaceuticals, Inc. (NASDAQ:PTBI) is a biopharmaceutical company focused on gene therapy and plasma-based products for severe and life- threatening rare diseases. This stock has thrived in 2015 after attracting the attention of billionaire investors such as George Soros. Recently the stock surged in price and has been up as much as 305% in the last 30 days. PTBI has also made several key announcements in the month of May that have seemingly ignited momentum for this stock:
1) (PTBI) Closes Abeona Therapeutics Acquisition on May 18th
2) Today May 20th (PTBI) announces orphan drug and rare pediatric disease designations from the FDA
3) Closed $10 Million in Financing on May 11th
4) May 15th The company released Q1 2015 financials
Alcobra Ltd. (NASDAQ:ADHD) has been another player in the burgeoning biotech space. This is an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) as well as Fragile X Syndrome. The stock has seen as much as a 29.3% price spike since March. The company released its Q1 2015 financials on May 6th: http://yhoo.it/1LlAKdY.
Retail investors know the volatility of small cap and micro cap stocks but biotech stocks specifically can be extremely volatile. There is profit to be made in the short term as most micro cap and small cap biotech companies are in early development stages. The time required to go through clinical trials is a lengthy one but in the mean time, companies like OXIS, PTBI and ADHD are working to continue to make headway in